ReNeuron boost as stem cell therapy for eye disease singled out for special … – Proactive Investors UK
|
ReNeuron boost as stem cell therapy for eye disease singled out for special …
Proactive Investors UK AIM-listed ReNeuron (LON:RENE) said it has received orphan drug status in the world’s two biggest markets for its stem cell therapy to tackle a rare degenerative eye disease. The award by regulatory authorities in the US and Europe covers ReN003, … |
